Clinical Trial Update: Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial updating nab-paclitaxel plus ramucirumab as second-line treatment for metastatic gastroesophageal cancer completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Cancer

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• Ramucirumab (ramucirumab)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Gastroesophageal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-07-01